Get started
Author

Joab Williamson

Observed name: Williamson, Joab
ORCID: 0000-0002-8306-1559
Observed ORCID: 0000-0002-8306-1559
OpenAlex ID: A5077294034
Economic and developmental impacts of FDA designations: a systematic review and meta-analysis
2025 · Joab Williamson, Syed Shahzad Hasan, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 11
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices
2023 · Joab Williamson, Alexander James Spicer · Drug Discovery Today · 7
Unveiling the impacts of FDA Breakthrough Therapy Designation: a dual-perspective examination of economic and developmental outcomes for biotechnology companies
2024 · Joab Williamson, Alexander James Spicer, et al. · Drug Discovery Today · 6
Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study
2025 · Amer Zeidan, Anthony Selwyn Stein, et al. · Blood · 5
PDF
The Effect of the RMAT Designation on Biotechnology Stock Prices, Drug Development Timelines and Outcomes: An Empirical Analysis
2024 · Joab Williamson, Alexander James Spicer, et al. · Journal of Pharmaceutical Research International · 4
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs
2026 · Amer M. Zeidan, Sofia Aakko, et al. · Expert Review of Anticancer Therapy · 3
Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis
2026 · Joab Williamson, Emma J Searle, et al. · BMJ Open · 2
Evaluating the impact of the FDA’s orphan drug designation on share prices of biotechnology companies
2023 · Joab Williamson, Alexander James Spicer · Drug Discovery Today · 2
Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study
2025 · Mika Kontro, Anthony Selwyn Stein, et al. · Blood · 1
PDF
Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges
2024 · Joab Williamson, Alexander Spicer, et al. · Applied Drug Research Clinical Trials and Regulatory Affairs · 1
PDF
Financial burden to patients and informal carers of myelodysplastic syndromes in England: a modelled analysis stratified by transfusion dependence
2026 · Joab Williamson, Emma Searle, et al. · Leukemia Research
Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher‐Risk MDS Drug Development
2026 · Amer M. Zeidan, Petri Bono, et al. · European Journal Of Haematology
PDF
Success Rates and Timelines of African-Inclusive Phase III Trials: A Retrospective Analysis
2025 · Joab Williamson · Preprints.org
PDF
The Ethics of Optimism: Managing Investor Expectations in Biotech and Pharma
2025 · Joab Williamson, Alexander Spicer · Springer eBooks
Small pharma vendor management practices in clinical trials: A case study within Faron Pharmaceuticals
2023 · Joab Williamson, Juho Jalkanen, et al. · Drug Discovery Today
Works count: 18
Citation count: 42
H-index: 4
I10-index: 1
Year
Topic
Type